{
    "id": 6458,
    "fullName": "ERBB3 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) mutant indicates an unspecified mutation in the ERBB3 (Her3) gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "mutant",
    "createDate": "05/20/2015",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13193,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 12.5% (2/16), and a median progression-free survival of 1.7 months in patients with advanced solid tumors harboring ERBB3 (HER3) mutations (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 6308,
                "profileName": "ERBB3 mutant"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10323,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, ERBB3 mutations were only detected in patients with muscle-invasive urothelial bladder cancer that responded to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",
            "molecularProfile": {
                "id": 6308,
                "profileName": "ERBB3 mutant"
            },
            "therapy": {
                "id": 5462,
                "therapyName": "Cisplatin + Gemcitabine + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 6477,
                "name": "invasive bladder transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8305,
                    "pubMedId": null,
                    "title": "Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.",
                    "url": "http://meetinglibrary.asco.org/content/179076-197"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18727,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of ERBB3 single nucleotide variants (SNVs) was associated with shorter progression-free survival (wild-type vs mutant, 3.75 vs 1.48 months, HR=1.59, p=0.176) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B), and SNVs in the cytoplasmic domain correlated with further decreased response (1.38 vs 4.07 months, HR=4.58, p<0.001) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33526,
                "profileName": "ERBB2 amp ERBB3 mut"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18729,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of ERBB3 single nucleotide variants (SNVs) was associated with shorter progression-free survival (wild-type vs mutant, 3.75 vs 1.48 months, HR=1.59, p=0.176) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B), and SNVs in the cytoplasmic domain correlated with further decreased response (1.38 vs 4.07 months, HR=4.58, p<0.001) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33527,
                "profileName": "ERBB2 over exp ERBB3 mut"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6308,
            "profileName": "ERBB3 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33526,
            "profileName": "ERBB2 amp ERBB3 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33527,
            "profileName": "ERBB2 over exp ERBB3 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}